China National Accord Medicines (SZSE:000028) Accounts Payable & Accrued Expense

: ¥22,002 Mil (As of Jun. 2023)

View and export this data going back to 1993. Start your Free Trial

China National Accord Medicines's quarterly accounts payable & accrued expense increased from Dec. 2022 (¥18,207 Mil) to Mar. 2023 (¥20,996 Mil) and increased from Mar. 2023 (¥20,996 Mil) to Jun. 2023 (¥22,002 Mil).

China National Accord Medicines's annual accounts payable & accrued expense increased from Dec. 2020 (¥17,491 Mil) to Dec. 2021 (¥19,110 Mil) but then declined from Dec. 2021 (¥19,110 Mil) to Dec. 2022 (¥18,207 Mil).

China National Accord Medicines Accounts Payable & Accrued Expense Historical Data

The historical data trend for China National Accord Medicines's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China National Accord Medicines Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Accounts Payable & Accrued Expense

11,887.56

14,595.05

17,490.86

19,110.04

18,207.44

China National Accord Medicines Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Accounts Payable & Accrued Expense																20,571.44	21,847.66	18,207.44	20,995.72	22,002.26

China National Accord Medicines Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

China National Accord Medicines (SZSE:000028) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » China National Accord Medicines Corp Ltd (SZSE:000028) » Definitions » Accounts Payable & Accrued Expense

Traded in Other Exchanges

200028:China

Address

No. 15, Ba Gua Si 4th Road, Accord Pharmaceutical Building, Futian District, Guangdong Province, Shenzhen, CHN, 518029

Website

http://www.szaccord.com.cn

China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.

China National Accord Medicines (SZSE:000028) Headlines

No Headlines